Immunomedics’ ASCENT Confirms Trodelvy’s Efficacy In Triple-Negative Breast Cancer

 
• By Mandy Jackson

After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.

Healthcare success and patients to succeed in medical care or successful doctor concept as a stethoscope solving a maze to hit the target and succeed as a 3D illustration.
Trodelvy could find its way to more TNBC patients based on Phase III data • Source: Shutterstock

More from Clinical Trials

More from R&D